Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli Lilly ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Diabetes and Obesity Drugs Fuel Eli Lilly Profit in the Final Quarter of 2024 Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments ...

Feb. 6, 2025 /PRNewswire/ -- Today, the American Diabetes Association ® (ADA ... The resources are part of a nationwide collaboration between Lilly and the ADA to destigmatize obesity and ...

INDIANAPOLIS — Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 ...

(AP Photo/Darron Cummings, File) Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better ...

Eli Lilly (NYSE:LLY) on Thursday reported its Q4 ... LLY’s GLP-1 therapy tirzepatide, branded as Mounjaro and Zepbound for diabetes and weight loss, respectively, powered the company’s Q4 ...

(AP) — Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the Indianapolis-based drugmaker came out with a mostly better-than ...